During the study period, only targeted therapies for EGFR+, ALK+, and ROS1+ NSCLC were available at public hospitals in Norway, and these were the subgroups with sufficient follow-up data to include in this study. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.